BIO2015: Resverlogix To Present At The 2015 BIO International Convention

TSX Exchange Symbol: RVX

CALGARY and PHILADELPHIA, June 17, 2015 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) (the "Company") today announced that Mr. Donald McCaffrey, president and chief executive officer will be presenting today at 10:15 am ET at the 2015 Bio International Convention. The presentation will be webcast and the replay will be available one hour after the live presentation. To access the webcast replay, please click here: http://www.veracast.com/webcasts/bio/internationalconvention2015/22203242375.cfm.

About RVX-208

RVX-208 is a first-in-class, small molecule selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with DM and low HDL.

About Resverlogix

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX.

Company Contacts:

Donald J. McCaffrey                                                                 
President and CEO                                                       
Resverlogix Corp.                                                                                             
Phone: 403-254-9252                            
Email: don@resverlogix.com                 

Sarah Zapotichny
Director of Investor Relations & Corporate Communications
Resverlogix Corp.
Phone : 403-254-9252
Email: sarah@resverlogix.com

SOURCE Resverlogix Corp.